Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Penelope Jane Hallett, Ph.D.

Co-Author

This page shows the publications co-authored by Penelope Hallett and Ole Isacson.
Connection Strength

9.128
  1. Novel Results and Concepts Emerging From Lipid Cell Biology Relevant to Degenerative Brain Aging and Disease. Front Neurol. 2019; 10:1053.
    View in: PubMed
    Score: 0.861
  2. Lipid and immune abnormalities causing age-dependent neurodegeneration and Parkinson's disease. J Neuroinflammation. 2019 Jul 22; 16(1):153.
    View in: PubMed
    Score: 0.848
  3. Glycosphingolipid levels and glucocerebrosidase activity are altered in normal aging of the mouse brain. Neurobiol Aging. 2018 07; 67:189-200.
    View in: PubMed
    Score: 0.774
  4. Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson's disease. Cell Stem Cell. 2015 Mar 05; 16(3):269-74.
    View in: PubMed
    Score: 0.625
  5. Long-term health of dopaminergic neuron transplants in Parkinson's disease patients. Cell Rep. 2014 Jun 26; 7(6):1755-61.
    View in: PubMed
    Score: 0.595
  6. a-Synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits. Neurobiol Dis. 2012 Aug; 47(2):258-67.
    View in: PubMed
    Score: 0.513
  7. No evidence for disease-like processes in fetal transplants. Proc Natl Acad Sci U S A. 2009 Sep 15; 106(37):E104; author reply E105.
    View in: PubMed
    Score: 0.427
  8. Fibroblasts from idiopathic Parkinson's disease exhibit deficiency of lysosomal glucocerebrosidase activity associated with reduced levels of the trafficking receptor LIMP2. Mol Brain. 2021 01 19; 14(1):16.
    View in: PubMed
    Score: 0.235
  9. Cell type-specific lipid storage changes in Parkinson's disease patient brains are recapitulated by experimental glycolipid disturbance. Proc Natl Acad Sci U S A. 2020 11 03; 117(44):27646-27654.
    View in: PubMed
    Score: 0.231
  10. Upregulating ß-hexosaminidase activity in rodents prevents a-synuclein lipid associations and protects dopaminergic neurons from a-synuclein-mediated neurotoxicity. Acta Neuropathol Commun. 2020 08 06; 8(1):127.
    View in: PubMed
    Score: 0.228
  11. Experimental studies of mitochondrial and lysosomal function in in vitro and in vivo models relevant to Parkinson's disease genetic risk. Int Rev Neurobiol. 2020; 154:279-302.
    View in: PubMed
    Score: 0.227
  12. Advantages and Recent Developments of Autologous Cell Therapy for Parkinson's Disease Patients. Front Cell Neurosci. 2020; 14:58.
    View in: PubMed
    Score: 0.223
  13. Mitochondrial clearance and maturation of autophagosomes are compromised in LRRK2 G2019S familial Parkinson's disease patient fibroblasts. Hum Mol Genet. 2019 10 01; 28(19):3232-3243.
    View in: PubMed
    Score: 0.215
  14. Neurite Collapse and Altered ER Ca2+ Control in Human Parkinson Disease Patient iPSC-Derived Neurons with LRRK2 G2019S Mutation. Stem Cell Reports. 2019 01 08; 12(1):29-41.
    View in: PubMed
    Score: 0.204
  15. Lipid-dependent deposition of alpha-synuclein and Tau on neuronal Secretogranin II-positive vesicular membranes with age. Sci Rep. 2018 10 12; 8(1):15207.
    View in: PubMed
    Score: 0.201
  16. The glycoprotein GPNMB is selectively elevated in the substantia nigra of Parkinson's disease patients and increases after lysosomal stress. Neurobiol Dis. 2018 12; 120:1-11.
    View in: PubMed
    Score: 0.199
  17. Glucocerebrosidase gene therapy prevents a-synucleinopathy of midbrain dopamine neurons. Neurobiol Dis. 2015 Oct; 82:495-503.
    View in: PubMed
    Score: 0.163
  18. Fibroblast Biomarkers of Sporadic Parkinson's Disease and LRRK2 Kinase Inhibition. Mol Neurobiol. 2016 10; 53(8):5161-77.
    View in: PubMed
    Score: 0.163
  19. Sustained Systemic Glucocerebrosidase Inhibition Induces Brain a-Synuclein Aggregation, Microglia and Complement C1q Activation in Mice. Antioxid Redox Signal. 2015 Aug 20; 23(6):550-64.
    View in: PubMed
    Score: 0.161
  20. A Nurr1 agonist causes neuroprotection in a Parkinson's disease lesion model primed with the toll-like receptor 3 dsRNA inflammatory stimulant poly(I:C). PLoS One. 2015; 10(3):e0121072.
    View in: PubMed
    Score: 0.157
  21. Progressive decline of glucocerebrosidase in aging and Parkinson's disease. Ann Clin Transl Neurol. 2015 Apr; 2(4):433-8.
    View in: PubMed
    Score: 0.156
  22. ALS-associated peripherin spliced transcripts form distinct protein inclusions that are neuroprotective against oxidative stress. Exp Neurol. 2014 Nov; 261:217-29.
    View in: PubMed
    Score: 0.149
  23. Widespread neuron-specific transgene expression in brain and spinal cord following synapsin promoter-driven AAV9 neonatal intracerebroventricular injection. Neurosci Lett. 2014 Jul 25; 576:73-8.
    View in: PubMed
    Score: 0.148
  24. Progressive axonal transport and synaptic protein changes correlate with behavioral and neuropathological abnormalities in the heterozygous Q175 KI mouse model of Huntington's disease. Hum Mol Genet. 2014 Sep 01; 23(17):4510-27.
    View in: PubMed
    Score: 0.147
  25. Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons. Stem Cells. 2013 Aug; 31(8):1548-62.
    View in: PubMed
    Score: 0.140
  26. Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson's disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression. Mol Cell Neurosci. 2012 Feb; 49(2):230-9.
    View in: PubMed
    Score: 0.125
  27. Development of histocompatible primate-induced pluripotent stem cells for neural transplantation. Stem Cells. 2011 Jul; 29(7):1052-63.
    View in: PubMed
    Score: 0.121
  28. The Toll-like receptor-3 agonist polyinosinic:polycytidylic acid triggers nigrostriatal dopaminergic degeneration. J Neurosci. 2010 Dec 01; 30(48):16091-101.
    View in: PubMed
    Score: 0.117
  29. Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats. Proc Natl Acad Sci U S A. 2010 Sep 07; 107(36):15921-6.
    View in: PubMed
    Score: 0.114
  30. Functional enhancement and protection of dopaminergic terminals by RAB3B overexpression. Proc Natl Acad Sci U S A. 2009 Dec 29; 106(52):22474-9.
    View in: PubMed
    Score: 0.109
  31. The blood-brain barrier is intact after levodopa-induced dyskinesias in parkinsonian primates--evidence from in vivo neuroimaging studies. Neurobiol Dis. 2009 Sep; 35(3):348-51.
    View in: PubMed
    Score: 0.105
  32. Implanted reuptake-deficient or wild-type dopaminergic neurons improve ON L-dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson's disease. Brain. 2008 Dec; 131(Pt 12):3361-79.
    View in: PubMed
    Score: 0.101
  33. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat Med. 2008 May; 14(5):507-9.
    View in: PubMed
    Score: 0.097
  34. Splice-Switching Antisense Oligonucleotides Reduce LRRK2 Kinase Activity in Human LRRK2 Transgenic Mice. Mol Ther Nucleic Acids. 2020 Sep 04; 21:623-635.
    View in: PubMed
    Score: 0.057
  35. Correction to: Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson's disease. Mol Neurodegener. 2020 Jan 15; 15(1):6.
    View in: PubMed
    Score: 0.055
  36. Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson's disease. Mol Neurodegener. 2019 11 08; 14(1):40.
    View in: PubMed
    Score: 0.054
  37. Enhanced ubiquitin-dependent degradation by Nedd4 protects against a-synuclein accumulation and toxicity in animal models of Parkinson's disease. Neurobiol Dis. 2014 Apr; 64:79-87.
    View in: PubMed
    Score: 0.036
  38. PSD-95 uncouples dopamine-glutamate interaction in the D1/PSD-95/NMDA receptor complex. J Neurosci. 2009 Mar 04; 29(9):2948-60.
    View in: PubMed
    Score: 0.026
  39. Inhibition of the dopamine D1 receptor signaling by PSD-95. J Biol Chem. 2007 May 25; 282(21):15778-89.
    View in: PubMed
    Score: 0.023
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.